<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468685</url>
  </required_header>
  <id_info>
    <org_study_id>12-2020</org_study_id>
    <nct_id>NCT04468685</nct_id>
  </id_info>
  <brief_title>Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy</brief_title>
  <official_title>Efficacy of Intraperitoneal Ondansetron Administration on Pain Relief After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hepatology &amp; Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hepatology &amp; Tropical Medicine Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic cholecystectomy (LC) is an easy procedure characterized by its minimal&#xD;
      invasiveness, less post-operative pain and early recovery when compared to the open&#xD;
      conventional cholecystectomy. However, patients who have undergone LC still complain of&#xD;
      postoperative pain. It has been reported that ondansetron produces numbness when injected&#xD;
      under the skin and has local anesthetic effect that is 15 times more potent than lidocaine&#xD;
      the most widely used local anesthetic and probably explains its antiemetic action. It&#xD;
      possesses anti-inflammatory, anesthetic, and analgesic properties by its multifaceted actions&#xD;
      as a 5-HT3 receptor antagonist, a Na channel blocker, and a mu-opioid agonist which may have&#xD;
      a potential role in decreasing pain. The study aimed to demonstrate the effectiveness of IP&#xD;
      administration of ondansetron on pain management post LC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in postoperative pain between the two groups using visual analogue score (VAS)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron intraperitoneal in the gall bladder bed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline intraperitoneal in the gall bladder bed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Interperitoneal administration in the gall bladder bed</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Interperitoneal administration in the gall bladder bed</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are scheduled to undergo elective LC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing chronic pain treatment&#xD;
&#xD;
          -  Previous allergic response to local anesthetics or 5-HT3 receptor antagonists&#xD;
&#xD;
          -  Patients who received analgesics or sedatives 24 h before scheduled surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The National Hepatology and Tropical Research medicine institute</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hepatology &amp; Tropical Medicine Research Institute</investigator_affiliation>
    <investigator_full_name>Doaa abdelaziz</investigator_full_name>
    <investigator_title>Lecturer of clinical pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

